On May 28, Agilent Technologies rose 8.31% overnight, trading at $125.47/share. The surge was driven by stronger-than-expected fiscal Q2 results and an upward revision to full-year profit guidance.

Agilent reported fiscal Q2 adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion, surpassing the expected $1.799 billion, up approximately 10.2% year-over-year. The company raised its full-year adjusted EPS guidance to $6.00–$6.10 on revenue of $7.39–$7.49 billion, up from the prior forecast of $5.90–$6.04. Management highlighted GLP-1 drug momentum driving roughly 20% year-to-date growth, while its Ignite efficiency program is expected to offset cost pressures in the second half. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, citing product cycle momentum and U.S. pharma reshoring tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)